Read a new publication from Oncowitan: Compound KYA1797K, known as a potent Wnt/β-catenin inhibitor, has been identified as a weak inhibitor of the PD-1/PD-L1 checkpoint, using molecular modeling and experimental binding studies. The compound binds to PD-L1 dimers
A potential off-target effect of the Wnt/β-Catenin inhibitor KYA1797K: PD-L1 binding and checkpoint inhibition, Biomedicine Hub (2023)
